Combined treatment with NTS1 and A2A receptor antagonists in Parkinson's disease should therefore lead to enhanced antiparkinson actions, since A2A receptor antagonists instead mainly target the A2AR-D2R heteroreceptor complexes. Here, ADORA2A is linked to Parkinson disease.